HTRA2 and Parkinson disease: The earliest mutation screening of HTRA2 in PD patients was done in a German population after the finding that targeted disruption of HTRA2 can cause neurodegeneration and a Parkinsonian phenotype in mice, which resulted in the identification of two mutations (G399S and A141S) related to the risk of PD [23, 24].